.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Mallinckrodt
Cerilliant
Novartis
Cipla
US Army
Medtronic
Cantor Fitzgerald
QuintilesIMS

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: ➤ Sign Up

« Back to Dashboard

Details for Patent: ➤ Sign Up

Title: Solubility parameter based drug delivery system and method for altering drug saturation concentration
Abstract:The method of adjusting the saturation concentration of a drug in a transdermal composition for application to the dermis, which comprises mixing polymers having differing solubility parameters, so as to modulate the delivery of the drug. This results in the ability to achieve a predetermined permeation rate of the drug into and through the dermis. In one embodiment, a dermal composition of the present invention comprises a drug, an acrylate polymer, and a polysiloxane. The dermal compositions can be produced by a variety of methods known in the preparation of drug-containing adhesive preparations, including the mixing of the polymers, drug, and additional ingredients in solution, followed by removal of the processing solvents. The method and composition of this invention permit selectable loading of the drug into the dermal formulation and adjustment of the delivery rate of the drug from the composition through the dermis, while maintaining acceptable shear, tack, and peel adhesive properties.
Inventor(s): Miranda; Jesus (Miami, FL), Sablotsky; Steven (Miami, FL)
Assignee: Noven Pharmaceuticals, Inc. (Miami, FL)
Filing Date:Mar 23, 1999
Application Number:09/274,886
Claims:1. A dermal composition, comprising a blend of:

(a) a polyacrylate and a second polymer selected from the group consisting of a polysiloxane and a hydrocarbon polymer; and

(b) a therapeutically effective amount of an androgenic steroid selected from the group consisting of methyltestosterone, fluoxymesterone and testosterone for transdermal administration, wherein the composition is a pressure-sensitive adhesive and the polyacrylate and the second polymer modulates the permeation rate of the androgenic steroid selected from the group consisting of methyltesterone, fluoxymesterone and testosterone through the dermis, and wherein the composition excludes a polyethylene/vinyl acetate copolymer.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Teva
US Department of Justice
Novartis
Daiichi Sankyo
Chinese Patent Office
Fish and Richardson
Medtronic
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot